Gilead Sciences (GILD) Competitors

Ligand Pharmaceuticals has a net margin of 46.42% compared to Gilead Sciences' net margin of 28.90%. Gilead Sciences' return on equity of 49.46% beat Ligand Pharmaceuticals' return on equity.

Gilead Sciences has higher revenue and earnings than Ligand Pharmaceuticals. Gilead Sciences is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

91.3% of Ligand Pharmaceuticals shares are held by institutional investors. Comparatively, 83.7% of Gilead Sciences shares are held by institutional investors. 7.0% of Ligand Pharmaceuticals shares are held by insiders. Comparatively, 0.3% of Gilead Sciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Gilead Sciences had 43 more articles in the media than Ligand Pharmaceuticals. MarketBeat recorded 58 mentions for Gilead Sciences and 15 mentions for Ligand Pharmaceuticals. Gilead Sciences' average media sentiment score of 0.93 beat Ligand Pharmaceuticals' score of 0.88 indicating that Gilead Sciences is being referred to more favorably in the news media.

Ligand Pharmaceuticals has a beta of 1.2, suggesting that its share price is 20% more volatile than the S&P 500. Comparatively, Gilead Sciences has a beta of 0.31, suggesting that its share price is 69% less volatile than the S&P 500.

Ligand Pharmaceuticals presently has a consensus target price of $256.29, indicating a potential upside of 10.21%. Gilead Sciences has a consensus target price of $157.35, indicating a potential upside of 15.44%. Given Gilead Sciences' higher probable upside, analysts clearly believe Gilead Sciences is more favorable than Ligand Pharmaceuticals.

In the previous week, Gilead Sciences had 5 more articles in the media than Moderna. MarketBeat recorded 58 mentions for Gilead Sciences and 53 mentions for Moderna. Gilead Sciences' average media sentiment score of 0.93 beat Moderna's score of 0.14 indicating that Gilead Sciences is being referred to more favorably in the news media.

75.3% of Moderna shares are held by institutional investors. Comparatively, 83.7% of Gilead Sciences shares are held by institutional investors. 10.8% of Moderna shares are held by insiders. Comparatively, 0.3% of Gilead Sciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Gilead Sciences has a net margin of 28.90% compared to Moderna's net margin of -143.55%. Gilead Sciences' return on equity of 49.46% beat Moderna's return on equity.

Moderna presently has a consensus target price of $35.73, indicating a potential downside of 26.76%. Gilead Sciences has a consensus target price of $157.35, indicating a potential upside of 15.44%. Given Gilead Sciences' stronger consensus rating and higher probable upside, analysts clearly believe Gilead Sciences is more favorable than Moderna.

Gilead Sciences has higher revenue and earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks.

Moderna has a beta of 1.05, suggesting that its share price is 5% more volatile than the S&P 500. Comparatively, Gilead Sciences has a beta of 0.31, suggesting that its share price is 69% less volatile than the S&P 500.

In the previous week, Gilead Sciences had 16 more articles in the media than Regeneron Pharmaceuticals. MarketBeat recorded 58 mentions for Gilead Sciences and 42 mentions for Regeneron Pharmaceuticals. Gilead Sciences' average media sentiment score of 0.93 beat Regeneron Pharmaceuticals' score of 0.69 indicating that Gilead Sciences is being referred to more favorably in the media.

83.7% of Gilead Sciences shares are owned by institutional investors. Comparatively, 83.3% of Regeneron Pharmaceuticals shares are owned by institutional investors. 0.3% of Gilead Sciences shares are owned by insiders. Comparatively, 7.0% of Regeneron Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Regeneron Pharmaceuticals has a net margin of 29.65% compared to Gilead Sciences' net margin of 28.90%. Gilead Sciences' return on equity of 49.46% beat Regeneron Pharmaceuticals' return on equity.

Gilead Sciences presently has a consensus price target of $157.35, indicating a potential upside of 15.44%. Regeneron Pharmaceuticals has a consensus price target of $826.59, indicating a potential upside of 14.64%. Given Gilead Sciences' stronger consensus rating and higher probable upside, research analysts plainly believe Gilead Sciences is more favorable than Regeneron Pharmaceuticals.

Gilead Sciences has higher revenue and earnings than Regeneron Pharmaceuticals. Regeneron Pharmaceuticals is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks.

Gilead Sciences has a beta of 0.31, indicating that its stock price is 69% less volatile than the S&P 500. Comparatively, Regeneron Pharmaceuticals has a beta of 0.3, indicating that its stock price is 70% less volatile than the S&P 500.

Gilead Sciences pays an annual dividend of $3.28 per share and has a dividend yield of 2.4%. Regeneron Pharmaceuticals pays an annual dividend of $3.76 per share and has a dividend yield of 0.5%. Gilead Sciences pays out 48.4% of its earnings in the form of a dividend. Regeneron Pharmaceuticals pays out 9.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Gilead Sciences has raised its dividend for 10 consecutive years. Gilead Sciences is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

In the previous week, Gilead Sciences had 49 more articles in the media than Vir Biotechnology. MarketBeat recorded 58 mentions for Gilead Sciences and 9 mentions for Vir Biotechnology. Gilead Sciences' average media sentiment score of 0.93 beat Vir Biotechnology's score of 0.43 indicating that Gilead Sciences is being referred to more favorably in the media.

83.7% of Gilead Sciences shares are held by institutional investors. Comparatively, 65.3% of Vir Biotechnology shares are held by institutional investors. 0.3% of Gilead Sciences shares are held by company insiders. Comparatively, 16.0% of Vir Biotechnology shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Gilead Sciences has a net margin of 28.90% compared to Vir Biotechnology's net margin of -638.88%. Gilead Sciences' return on equity of 49.46% beat Vir Biotechnology's return on equity.

Gilead Sciences has a beta of 0.31, suggesting that its share price is 69% less volatile than the S&P 500. Comparatively, Vir Biotechnology has a beta of 1.7, suggesting that its share price is 70% more volatile than the S&P 500.

Gilead Sciences presently has a consensus price target of $157.35, indicating a potential upside of 15.44%. Vir Biotechnology has a consensus price target of $20.38, indicating a potential upside of 98.01%. Given Vir Biotechnology's stronger consensus rating and higher probable upside, analysts plainly believe Vir Biotechnology is more favorable than Gilead Sciences.

Gilead Sciences has higher revenue and earnings than Vir Biotechnology. Vir Biotechnology is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks.